how to manage and report aes associated with bispecific antibody treatment in myeloma
Published 1 month ago • 79 plays • Length 6:15Download video MP4
Download video MP3
Similar videos
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
2:06
improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma
-
1:01
considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
2:22
cmv reactivation during treatment with bispecifics for r/r myeloma
-
1:52
improving the outcomes of transplantation with bispecific antibodies
-
58:27
laboratory nonconformance (event) management
-
3:20
bispecific antibody
-
45:42
what you need to know about bispecific antibody immunotherapy
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
1:53
sequencing car t-cells and bispecific antibodies in the treatment of multiple myeloma
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
3:07
advice for community hematologists when prescribing bispecific antibodies for multiple myeloma
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
3:07
developing guidelines for the management of infections following treatment with bispecifics
-
1:37
the promise of elranatamab and other bispecifics in the treatment of myeloma
-
1:51
how to manage tumor flare after administration of bispecific antibodies
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma